Acadia Pharmaceuticals Inc - Company & Market Research Reports

Acadia Pharmaceuticals is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease, Phase II trial for the treatment of schizophrenia and Phase II study for the treatment of Alzheimer's disease. The company was founded in 1993 and is headquartered in San Diego, California.

From
From
Neuropathic Pain - Pipeline Review, H2 2017 - Product Thumbnail Image

Neuropathic Pain - Pipeline Review, H2 2017

  • Drug Pipelines
  • 488 Pages
From
Neuropathic Pain - Pipeline Review, H1 2017 - Product Thumbnail Image

Neuropathic Pain - Pipeline Review, H1 2017

  • Drug Pipelines
  • 485 Pages
From
From
From
From
From
From
From
From
From
From
From
From
Dementia - Pipeline Review, H2 2018 - Product Thumbnail Image

Dementia - Pipeline Review, H2 2018

  • Drug Pipelines
  • 302 Pages
From
Dementia - Pipeline Review, H1 2018 - Product Thumbnail Image

Dementia - Pipeline Review, H1 2018

  • Drug Pipelines
  • 260 Pages
From
Loading Indicator
adroll